Andrew Hendifar
Overview
Explore the profile of Andrew Hendifar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
3412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monson S, Chen P, Gangi A, Waters K, Billet S, Hendifar A, et al.
Transl Gastroenterol Hepatol
. 2025 Feb;
10:11.
PMID: 39944579
Background And Objective: Globally, colorectal cancer (CRC) is the third most commonly diagnosed cancer. CRC is known to arise from precancerous polyps known as adenomas. Although there are genetic syndromes...
2.
Burley N, Lee Y, Liu L, Gangi A, Nasseri Y, Atkins K, et al.
Immunotherapy
. 2024 Nov;
16(20-22):1197-1202.
PMID: 39552190
Circulating tumor DNA (ctDNA) represents a powerful measure of minimal residual disease (MRD) in colorectal cancer (CRC). Although immunotherapy has been widely established in metastatic CRC that is mismatch repair...
3.
Ahmed M, Larson B, Osipov A, Azad N, Hendifar A
Oncotarget
. 2024 Oct;
15:741-747.
PMID: 39392392
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths, with adenosquamous carcinoma of the pancreas (ASCP), a rare variant, representing 1-10% of cases. Standard chemotherapy trials for pancreatic...
4.
Liang J, Rastegar R, Helou M, Mathur K, Larson B, Waters K, et al.
Am J Gastroenterol
. 2024 Sep;
PMID: 39225338
Introduction: Upper gastrointestinal (UGI) cancers, comprising malignancies of the esophagus, stomach, duodenum, pancreas, liver, biliary tract, and gallbladder, are the second leading cause of cancer-related mortality in the United States...
5.
Kaur B, Yeo Y, Liang J, Luu M, Ayoub W, Kuo A, et al.
Gastro Hep Adv
. 2024 Aug;
3(2):230-237.
PMID: 39129956
Background And Aims: The change in hepatocellular carcinoma (HCC) care continuum during the coronavirus disease 2019 (COVID-19) pandemic remains unknown at a national level in the United States. We sought...
6.
Liang J, Li P, Norman J, Lauzon M, Yeo Y, Trivedi H, et al.
Hepatol Commun
. 2024 Jun;
8(7).
PMID: 38896084
Background: Serum AFP-L3%, AFP, and DCP are useful biomarkers for HCC detection, but their utility in assessing treatment response remains unknown. We aim to evaluate the accuracy of a biomarker...
7.
Hendifar A, Hitchins M, Lauzon M, Hatchell K, Heald B, Pandol S, et al.
HPB (Oxford)
. 2024 Jun;
26(8):1082-1085.
PMID: 38825435
No abstract available.
8.
Wang J, Cui Y, Osipov A, Gong J, Pandol S, Lo S, et al.
Clin Transl Gastroenterol
. 2024 Jun;
15(7):e00719.
PMID: 38822798
Introduction: Pancreatic ductal adenocarcinoma is associated with significant morbidity and mortality as most patients present with advanced disease. The development of ascites has been associated with poor outcomes and further...
9.
Russo A, DiPeri T, Dumitra T, Tseng J, Pletcher E, Justo M, et al.
J Neuroendocrinol
. 2024 May;
36(8):e13399.
PMID: 38760997
Patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET) often present with advanced disease. Primary tumor resection (PTR) in the setting of unresectable metastatic disease is controversial. Most studies evaluating the impact...
10.
Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Pena L, Leiton C, Hasan M, et al.
J Transl Med
. 2024 May;
22(1):443.
PMID: 38730319
Background: The immune microenvironment impacts tumor growth, invasion, metastasis, and patient survival and may provide opportunities for therapeutic intervention in pancreatic ductal adenocarcinoma (PDAC). Although never studied as a potential...